A once-a-day controlled release drug delivery system of diltiazem hydrochloride is provided, which is bioequivalent in plasma profile of Cardizem CD. The fast, medium, and slow release fractions are prepared using various compositions and weight gains. The individual fill weights are computed and then are filled into the same capsule using specialized encapsulation equipment using a triple-filling process. A preferred membrane dispersion that is used for preparing the fast release fraction contains 0.2% of sodium lauryl sulfate along with 20% of water soluble plasticizer (triethyl citrate), and 2% silicone dioxide, based on quaternary polymethacrylate on the weight basis. This combination provides an initial pulsatile burst after a lag time of 2 hours, leading to in-vivo bioequivalence. The preferred membrane dispersion that is used for preparing the medium release and the slow release fractions contain 16% of water soluble plasticizer along with 5% silicone dioxide, based on quaternary polymethacrylate. This combination provides an optimal glass transition temperature that allows for the preparation of exceptionally increased weight gains. Additionally, it provides targeted input of drug release for achieving bioequivalence. Regardless of significant in-vitro inequivalence to the release rate profile of the innovator product, the in vivo-equivalence data comply with required regulatory guidelines.
本研究提供了一种
盐酸地尔硫卓的一日一次控释给药系统,其血浆特征与 Cardizem CD 具有
生物等效性。使用不同的成分和重量增量制备了快释、中释和缓释馏分。计算出各个填充重量后,使用专门的封装设备,采用三重填充工艺将其填充到同一个胶囊中。用于制备快速释放部分的优选膜分散体含有 0.2% 的
十二烷基硫酸钠和 20% 的
水溶性
增塑剂(
柠檬酸三乙酯),以及 2% 的
二氧化硅(以季
铵聚
甲基丙烯酸酯的重量为基础)。这种组合可在滞后 2 小时后提供初始脉冲爆发,从而实现体内
生物等效性。用于制备中释和缓释馏分的优选膜分散体含有 16% 的
水溶性
增塑剂和 5% 的
二氧化硅(以季
铵型聚
甲基丙烯酸酯为基础)。这种组合提供了最佳的
玻璃化转变温度,使制备的增重效果特别好。此外,它还能有针对性地释放药物,实现
生物等效性。尽管体外试验与创新产品的释放率曲线存在明显的不等效性,但体内等效性数据符合规定的监管准则。